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Abstract
Epidemiological differences exist betweenMycobacterium africanum (Maf)- andMycobac-
terium tuberculosis (Mtb)-infected patients, but to date, contributing host factors have not
been characterised. We analysed clinical outcomes, as well as soluble markers and gene
expression profiles in unstimulated, and ESAT6/CFP-10-, whole-Maf- andMtb-stimulated
blood samples of 26Maf- and 49Mtb-HIV-negative tuberculosis patients before, and after 2
and 6 months of anti-tuberculosis therapy. Before treatment, both groups had similar clinical
parameters, but differed in few cytokines concentration and gene expression profiles. Fol-
lowing treatment the body mass index, skinfold thickness and chest X-ray scores showed
greater improvement in theMtb- compared toMaf-infected patients, after adjusting for age,
sex and ethnicity (p = 0.02; 0.04 and 0.007, respectively). In addition, in unstimulated blood,
IL-12p70, IL12A and TLR9 were significantly higher inMaf-infected patients, while IL-15, IL-
8 and MIP-1α were higher inMtb-infected patients. Overnight stimulation with ESAT-6/
CFP-10 induced significantly higher levels of IFN-γ and TNF-α production, as well as gene
expression of CCL4, IL1B and TLR4 inMtb- compared toMaf-infected patients. Our study
confirms differences in clinical features and immune genes expression and concentration of
proteins associated with inflammatory processes betweenMtb- andMaf-infected patients
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following anti-tuberculosis treatment These findings have public health implications for
treatment regimens, and biomarkers for tuberculosis diagnosis and susceptibility.
Author Summary
In the Gambia tuberculosis is caused my two major lineages within theMycobacterium
tuberculosis complex (MTBC),M. tuberculosis lineages 4 andM. africanum lineage 6. Our
analysis of 26M. africanum- and 49M. tuberculosis -HIV-negative tuberculosis patients’
clinic parameters and antigen-stimulated blood cytokines concentration and genes expres-
sion reveal that heterogeneous response to standard anti-tuberculosis treatment might
depend on the diversity of MTBC lineages. Before treatment, the two groups of patients
had similar clinical parameters, but greater improvement was observed inM. tuberculosis-
compared toM. africanum -infected patients post-treatment. This was supported by
higher production of inflammation-associated cytokines and genes in unstimulated blood
samples fromM. africanum-infected patients compared to those infected withM. tubercu-
losis, who instead had higher level of disease resolution cytokines. In contrast, there were
lower cytokine responses in antigen-stimulated blood samples ofM. africanum- compared
toM. tuberculosis-infected patients post-treatment indicating a poorly recovered immune
profile. Our results suggest thatM. africanum patients respond relatively poorly to the
standard anti-tuberculosis treatment or might have a pre-existing defective immune pro-
file; this could explain why they succumb to less virulent mycobacteria.
Introduction
Mycobacterium africanum (Maf) is an ancient lineage of theMycobacterium tuberculosis (Mtb)
Complex (MTBC), mostly found in West Africa where it causes up to half of all tuberculosis
(TB) cases [1]. Apart from descriptions of the epidemiological differences betweenMaf and
Mtb infection in the human population, differences in underlying immune responses, clinical
course and outcome of TB therapy have not been described [2]. Other authors have recently
attempted to define biomarkers that are able to predict treatment outcome and if validated,
these biomarkers could significantly shorten trials of new TB regimens [3–5]. Ultimately, the
performance of such biomarkers might be influenced by the infecting mycobacterial lineage.
Previous studies that have assessed whether the rate of response to treatment differs between
infecting MTBC lineages obtained conflicting results [6–13], but data from our own laboratory
and others [6,12,13] indicate that their responses to treatment are heterogeneous. Different
MTBC lineages may have been responsible for the heterogeneous response to the shorter TB
treatment regimen containing Gatifloxacin recently tested in West Africa [14].
We have previously shown that although the proportion of activated T cells were similar in
Maf- andMtb-infected patients pre-treatment, they decreased significantly inMtb-infected
patients, while those ofMaf-infected patients were persistently high but consisted of poorly
functional T cells post-treatment [15]. In addition, the transcriptomic and metabolic profiles of
Maf- andMtb-infected patients while similar at baseline significantly differed by lineage post-
treatment mainly due to changes inMtb-infected but not inMaf-infected patients [13]. These
results suggest that intrinsic host factors determine the immune response to TB and/or differ-
ential effect of the standard anti-TB treatment on the two lineages.
This study was conducted to investigate the changes in the host immune response and clini-
cal outcomes following treatment in a larger cohort ofMaf- andMtb-infected tuberculosis
Maf andMtb-Infected Patients’ Immune Responses after Treatment
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004701 May 18, 2016 2 / 20
and archives staffs who will rapidly reply to any
request.
Funding: The study was funded by the MRC Unit,
The Gambia as a PhD fellowship awarded to LDT.
Financial support for these studies was obtained from
projects EC FP7 IDEA, EC FP7 ADITEC, EC FP7
NEWTBVAC and EC HOR2020 TBVAC2020. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
patients before, during and after standard anti-TB treatment. Although we found no differ-
ences in the clinical parameters measured and found differences in only few cytokines concen-
tration and gene expression profiles betweenMaf- andMtb-infected patients pre-treatment,
many of these showed significant differences post-treatment suggesting either intrinsic lineage-
specific difference in response to standard anti-TB therapy and/or in the underlying host
immunity.
Methods
Ethics statement
Ethical approval was obtained from The Joint Gambian Government/Medical Research Coun-
cil (MRC) Ethics Committee in The Gambia and the London School of Hygiene & Tropical
Medicine Ethics Committee. All patients provided written informed consent.
Study participants
Sputum smear and culture positive TB patients were recruited at the TB Clinic, MRC Unit,
Fajara, The Gambia. On recruitment, we recorded clinical symptoms using a questionnaire
that included duration of cough, weight lost, night sweats, and fever; routine clinical assess-
ment including anthropometry (weight, height, skinfold thickness (SFK) and body mass index
(BMI)), and tuberculin skin test (TST), as previously reported [16]. Sputum was sent for TB
smear and culture. The genotypes of the infecting bacilli in sputum were determined by spoli-
gotyping analysis and assessing the presence or absence of lineage defining Large Sequence
Polymorphisms (LSP) RD702 and TbD1 as previously described [15,17]. All patients were
HIV-negative with no history of previous TB disease and were enrolled before anti-TB treat-
ment. All patients received conventional therapy of 2 months intensive treatment with Isonia-
zid, Rifampicin, Pyrazinamide, Ethambutol, followed by a second phase of four months with
only Isoniazid and Rifampicin (2HRZE/4HR) [18]. They were actively followed-up at 2 and 6
months of treatment, during which chest x-ray (CXR), haematological and sputum smear
examination, and anthropometric measurements were done, and heparinized blood samples
collected. All patients were confirmed sputum smear negative at the end of the 6 months
treatment.
Whole blood stimulation and multiplex cytokine assays
Undiluted whole blood (180 μL) was incubated overnight (16 hours) in duplicate with 20 μL of
medium alone or phytohaemagglutinin (PHA-L, Sigma-Aldrich, UK; 5 μg/ml), purified pro-
tein derivative (Mtb-PPD; Staten Serum Institute, Denmark; 10 μg/ml), ESAT-6/CFP-10 pep-
tides pool [(EC, ProImmune, UK; 2.5 μg/mL/peptides), EC amino acid sequence is identical in
Maf andMtb lineages [19], or whole mycobacteriaMtbH37Rv andMaf GM041182 used both
live [final multiplicity of infection (MOI) 1:2 (bacteria: monocytes) and heat-killed (6 x 105
cfu/mL)] [15].
After overnight culture, supernatants were collected from each well, TriReagent (Ambion,
Foster City, USA) was added to the pellet, and both were stored at -20°C till analysis. The
supernatants were analysed using a Bio-Plex Pro 27-plex kit (cat# M50OKCAFOY, BIO-RAD
Laboratories; Belgium) for IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-
10, IL-12p70, IL-13, IL-15, IL-17A, Eotaxin (CCL11), Basic FGF, granulocyte colony-stimulat-
ing factor [G-CSF], granulocyte-macrophage CSF [GM-CSF], IFN-γ, IP-10 (CXCL10), MCP-1
(CCL2), MIP-1α (CCL3), MIP-1β (CCL4), PDGF-ββ, RANTES (CCL5), TNF-α, and VEGF
following the standard protocol provided by the manufacturers. Plates were immediately read
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on the Bio-Plex reader using Bio-Plex Manager software (version 4.1.1; Bio-Rad, USA) with
five-parameter logistic (5-PL) algorithms and a low PMT setting. All standards were run in
duplicate. OOR> and OOR< values were assigned the highest and lowest standard values mul-
tiplied or divided by 2 respectively.
RNA extraction and dual colour Reverse Transcription Multiplex
Ligation-dependent Probe Amplification (dcRT-MLPA)
RNA was isolated from stimulated blood pellets lysed in TriReagent (Ambion, Foster City,
USA) using a Chloroform/RNeasy (Qiagen, Crawley, UK) protocol following manufacturer’s
instructions. Dual colour RT-MLPA was performed as described previously [20,21]. Briefly,
100–150 ng RNA was reverse transcribed using 80nM of target-specific RT primers, 1x MMLV
reverse transcriptase and 0.4 mM of each dNTP. cDNA was denatured and hybridized over-
night at 60°C with 4 nM of probe mix containing left- and right-hand probes of 85 genes. After
ligating the hybridized probes with ligase-65 for 15 min at 54°C, PCR amplification of the liga-
tion products was performed with specific SALSA FAM-labelled MLPA primers, HEX-labelled
MAPH primers (1 μL of 2 μM each, forward primer 5’-GGCCGCGGGAATTCGATT-3’ and
reverse primer 5’-GCCGCGAATTCACTAGTG-3’), 14.75 μL H20 and 0.25 μL SALSA poly-
merase. Primers and probes were from Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands)
and MLPA SALSA reagents fromMRC-Holland (Amsterdam, The Netherlands). Thermal
cycling conditions were 33 cycles of 30s at 95°C, 30s at 58°C and 60s at 72°C, followed by 1
cycle of 20min at 72°C. PCR products were diluted 1:10 in HiDi formamide containing 400
HD ROX size standard and analysed on an Applied Biosystems 3730 capillary sequencer in
GeneScan mode (Applied Biosystems, Foster City, USA).
Data were analysed using GeneMapper 4.0 software package (Applied Biosystems, Warring-
ton, UK) and peak areas were exported to a Microsoft Excel file for downstream analysis. Data
were subsequently normalized to GAPDH housekeeping gene and signals below the threshold
value for noise cut-off (peak area #200) were assigned threshold value for noise cut-off. A posi-
tive control that encompassed the complement reverse sequence of the combined target-spe-
cific sequences of the left and right hand half-probes was used for all runs.
Statistical analysis
Demographic and clinical characteristics were compared betweenMaf- andMtb-infected
patients using Mann-Whitney test for continuous variables and Fisher’s exact test for categori-
cal variables. BMI, skinfold thickness and haematology parameters were logarithmically trans-
formed. No transformation was needed for the chest X-ray score [16], and all were analysed
using a random intercept model based on restricted maximum likelihood (REML) estimation.
The cytokine responses were positively skewed and contained zero as values. We first added
a constant 0.5 to all cytokine responses as suggested by Yamamura [22], then used a base-2 log-
arithmic transformation to reduce skewness. Three-level random-intercept model (time points
nested in cytokines nested in patients) was fitted to account for the dependence of the cytokine
responses within subject and between time points. The model included triple interaction terms
between cytokines, lineages, stimulants and time points to estimate the difference in infecting
lineages effect on cytokine production in blood incubated with medium alone, as well as the
incremental difference in infecting lineages effect induced by each stimulant at each treatment
time points. This approach did not require any background subtraction. Contrast analysis was
used to estimate differences in infecting lineages effect on cytokine production with Sidak mul-
tiple comparison correction [23].
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Gene expression data were available for each subject at the same time points as for the cyto-
kines. At each time point, the effect of the four culture conditions (Medium, ESAT-6/CFP-10,
liveMaf and liveMtb) on the expression of 85 selected immune-related genes were assessed.
Thirty (30) genes showed expression data above the cut-off value (200) for1% of the patients
and were discarded from the analysis to avoid inflation of the cut-off value. The remaining 55
genes were log2 transformed and analysed as described for cytokines’ data.
Predicted values of clinical outcomes, cytokines production and genes expression from the
constructed model were used to study kinetics following anti-TB treatment for each group and
plotted using R software. We tested for interaction between lineages and treatment time points
using the Wald test. All analyses were adjusted for age, gender and ethnicity and performed
using STATA 12.1 (StataCorp, USA). Statistical significance was considered at p-value0.05.
Results
Study participants
Seventy-five HIV-negative TB patients were enrolled in this study, 26 were infected withMaf-
lineage 6 and 49 withMtb-lineage 4. Before treatment,Maf- andMtb-infected patients had
similar clinical symptoms, age, sex, ethnicity, sputum smear microscopy grade and TST results
(Table 1). The BMI, skinfold thickness and CXR scores were also similar in both groups at
enrolment, but following treatment these were more significantly improved inMtb- compared
toMaf-infected patients post-treatment after adjusting for age, sex and ethnic group (p = 0.02,
p = 0.04 and p = 0.007 respectively; Table 1). The BMI and CXR scores were significantly
affected by the infecting lineages following treatment (interaction p = 0.006 and p = 0.02
respectively; Fig 1). Mean corpuscular volume (MCV) was significantly higher inMtb- com-
pared toMaf-infected patients before and post-treatment after adjusting for the mentioned
potential confounders (p = 0.02 and p = 0.03; respectively), while all other measured haematol-
ogy parameters were similar between the groups (Table 1). The monocytes/lymphocytes (M:L)
ratio was similar before treatment but higher inMaf- compared toMtb-infected patients post-
treatment after adjusting for confounders (p = 0.05 respectively; Table 1).
Maf- andMtb-infected patients’ cytokine response to stimulants differs
after treatment
Before treatment, only stimulation with ESAT-6/CFP-10 induced a significant difference and
this was seen only for RANTES (CCL5) production, which was higher inMaf- compared to
Mtb-infected patients (p = 0.03; Fig 2; S1 Table). In contrast, many cytokines showed signifi-
cantly different responses betweenMtb- andMaf-infected patients post-treatment. In unstimu-
lated blood supernatants, concentrations of IL-8 (p = 0.013), IL-15 (p = 0.01) and MIP-1α
(p = 0.027) were significantly higher inMtb- compared toMaf-infected patients (Fig 2; S2
Table), whereas IL-12p70 (p = 0.002) and PDGF-β (p = 0.097) were higher inMaf- compared
toMtb-infected patients. Stimulation with ESAT-6/CFP-10 induced the greatest differences in
cytokines production between the two groups. IFN-γ (p = 0.022), TNF-α (p = 0.042), IL-2
(p = 0.093), IL-1ra (p = 0.093), and GM-CSF (p = 0.096) were higher inMtb- compared to
Maf-infected patients after Sidak multiple comparisons correction (Fig 2; S2 Table).
Kinetics of specific cytokines production following treatment ofMtb- and
Maf-infected patients
The kinetics of differentially produced cytokines between the groups was assessed in order to
understand the effect of treatment on cytokine responses in each group. In the unstimulated
Maf andMtb-Infected Patients’ Immune Responses after Treatment
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Table 1. Demographic, clinical and haematology characteristics ofM. africanum andM. tuberculosis patients.
M. africanum M. tuberculosis Unadjusted Adjusted
n Positive n Positive ED (95%CI) P AED (95%CI) P
Number of cases at enrolmenta 26 (35) 49 (65)
Age in years, median (range) 26 30.5 (19–66) 49 27 (15–79) 0.39
Sex (%) (Female) 26 8 (27) 49 20 (38) 0.40
Ethnicity (%) 26 49 0.50
Mandinka 8 (27) 23 (43)
Jola 10 (33) 5 (9) 0.084
Fula 4 (13) 10 (19) 0.89
Wolof 3 (10) 6 (12) 0.79
Other 5 (17) 9 (17) 0.89
Maximum smear grade (%) 26 49 0.18
1+ 5 (19) 3 (6)
2+ 6 (23) 18 (37) 0.066
3+ 15 (58) 28 (57) 0.16
TST 13 12 (92) 28 24 (89) 0.40
BMI, median (range)
Enrolment 26 18.6 (13–22) 49 18.6 (13–32) 0.04 (-0.04,0.12) 0.28 0.04 (-0.05,0.13) 0.39
6 months 14 18.6 (17–21) 25 20.2 (17–36) 0.12 (0.04,0.2) 0.004 0.11 (0.02,0.20) 0.02
Skinfold thickness median (range) in mm
Enrolment 26 8 (3–20) 49 8 (3–20) 0.08 (-0.08,0.25) 0.33 0.03 (-0.17,0.23) 0.76
6 months 14 8.5 (3–20) 27 14 (2–25) 0.2 (0.07,0.4) 0.006 0.28 (-0.01,0.55) 0.04
Chest X-Ray (Moderate & Severe Disease)
Enrolment 26 21 (81) 48 44 (92) 0.009 (-0.2,0.3) 0.94 0.05 (-0.25,0.35) 0.74
6 months 11 7 (64) 18 2 (11) -0.55 (-0.8, -0.3) 0.000 -0.55 (-0.95, -0.15) 0.007
Haematology parameter median (range)
Haemoglobin (mg/dL) Enrolment 26 11.5 (8.7–14.6) 43 10.7 (7.5–14.2) -0.06 (0.13, -003) 0.06 -0.06 (-0.12, 0.01) 0.09
6 months 20 13.4 (11.5–16.8) 30 13.7 (11.3–23.1) 0.01 (-0.06, 0.08) 0.80 0.01 (-0.06, 0.08) 0.74
WBC (x109/L) Enrolment 26 7.2 (3.8–19.4) 43 7.6 (3.6–15.3) 0.1 (-0.06, 0.26) 0.20 0.10 (-0.07, 0.26) 0.24
6 months 20 5.2 (3.2–7.8) 30 4.9 (2.4–8.4) -0.04 (-0.23, 0.14) 0.63 -0.05 (-0.24, 0.13) 0.56
Granulocytes (x109/L) Enrolment 26 4.3 (1.2–15.8) 43 5.5 (1.4–11.4) 0.21 (-0.07, 0.49) 0.13 0.19 (-0.10, 0.47) 0.20
6 months 20 3 (0.9–13.1) 30 3.4 (1.4–5.7) -0.02 (-0.33, 0.29) 0.89 -0.03 (-0.34, 0.29) 0.87
Lymphocytes (x109/L) Enrolment 26 1.5 (0.3–8.1) 43 1.7 (0.6–4.2) 0.08 (-0.16, 0.33) 0.50 0.09 (-0.17, 0.34) 0.50
6 months 20 2.8 (0.8–6.3) 30 3.7 (1.6–8.6) 0.03 (-0.25, 0.32) 0.82 0.02 (-0.28, 0.31) 0.91
Monocytes (x109/L) Enrolment 26 0.5 (0.3–1.4) 43 0.5 (0.1–1.2) 0.008 (-0.20, 0.21) 0.93 -0.004 (-0.22, 0.21) 0.97
6 months 20 0.7 (0.3–1.4) 30 0.6 (0.3–1.4) -0.20 (-0.43, 0.04) 0.1 -0.21 (-0.45, 0.03) 0.08
M:L ratio Enrolment 26 0.31 (0.12–1.14) 43 0.29 (0.06–0.87) -0.06 (-0.30, 0.18) 0.64 -0.06 (-0.30, 0.19) 0.65
6 months 20 0.23 (0.11–0.62) 30 0.18 (0.08–0.45) -0.27 (-0.55, -0.001) 0.049 -0.27 (-0.54, 0.005) 0.05
MCV (fL) Enrolment 25 77.8(59.2–92.5) 42 79.6 (60.6–92.9) 0.02 (-0.02, 0.07) 0.29 0.05 (0.004, 0.09) 0.03
6 months 20 83.7 (67.6–94.8) 30 85.1 (69.3–97.9) 0.04 (-0.01, 0.08) 0.15 0.06 (0.01, 0.10) 0.02
Platelets (x109/L) Enrolment 26 376 (131–678) 43 410 (101–663) 0.09 (-0.08, 0.26) 0.30 0.09 (-0.09, 0.26) 0.33
6 months 20 238 (161–355) 30 230 (74–387) -0.06 (-0.25, 0.13) 0.51 -0.07 (-0.26, 0.13) 0.50
a Total number of patients recruited = 75.
Abbreviations: BMI, body mass index; CXR, chest X-ray; 1+, 2+ & 3+ = Density of Mycobacteria into patient sputum; TST: tuberculin skin test, Maf = M.
africanum; Mtb = M. tuberculosis; WBC = white blood cells, MCV = mean corpuscular volume, M:L: monocytes/lymphocytes ratio, ED = Estimated
Difference between Mtb vs. Maf-infected patients, AED = Adjusted ED.
Signiﬁcant p-values are highlighted in bold.
doi:10.1371/journal.pntd.0004701.t001
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samples, the patterns of IL-12p70 and IL-15 were similar at 2 months, but differed significantly
at 6 months of treatment, whereas those of IL-8, MIP-1α and PDGF-ββ differed already at 2
months of treatment between the groups (interaction p<0.001; Fig 3A). In response to ESAT-
6/CFP-10 stimulation, the patterns of IFN-γ and GM-CSF were significantly different between
the groups at 2 months of treatment (interaction p<0.01; Fig 3B).
Differences in gene expression profiles betweenMaf- andMtb-infected
patients following treatment
Prior to treatment, there were significantly higher expression of IL13 in unstimulated
(p = 0.035), and BPI in ESAT-6/CFP-10 stimulated (p = 0.02) whole blood samples inMaf-
compared toMtb-infected patients (Fig 4, S3 Table). Likewise, post-treatment, TLR9 and
IL12A expression were significantly higher inMaf- compared toMtb-infected patients in the
unstimulated whole blood (p = 0.004 and p = 0.007 respectively; Fig 4, S4 Table). ESAT-6/
CFP-10 stimulation induced significantly higher expression of IL1B (p = 0.01), CCL4
(p = 0.006), TLR4 (p = 0.03) and CXCL10 (p = 0.06) inMtb- compared toMaf-infected
patients. Furthermore, stimulation with liveMaf induced higher expression of TBX21
(p = 0.03), NLRC4 (p = 0.06), ZNF331 (p = 0.06), IL23A (p = 0.07) and TLR4 (p = 0.08) inMtb-
thanMaf-infected patients (Fig 4, S4 Table).
Kinetics of gene expression inMaf- andMtb-infected patients following
treatment
In unstimulated whole blood, the patterns of TLR9 and IL12A expression were significantly dif-
ferent betweenMaf andMtb-infected patients at 2 months of treatment (interaction p = 0.004
and p = 0.0005 respectively; Fig 5A). In ESAT-6/CFP-10 stimulated whole blood, the kinetics
of CXCL10 expression differed between the groups at 2 months of treatment (interaction
p = 0.04; Fig 5B), while following liveMaf stimulation, the kinetics of NLRC4 expression was
significantly different at 2 month of treatment between the groups (interaction p = 0.0007;
Fig 5C).
Fig 1. Kinetics of the clinical outcomes inMaf- andMtb-infected patients following treatment. Line plots show the predicted mean and its 95% CI of
Log transformed Body Mass Index (BMI) and Skinfold Thickness (SFT) inMaf- andMtb-infected groups at 0, 2 and 6 months of treatment, Chest X-ray
(CXR) was not Log transformed. Wald test through contrasts analysis following a random-intercept model adjusted for age, sex and ethnicity was used to
assess interaction between lineage group and time point on clinical response.Maf group (dashed lines) andMtb group (solid lines) respectively. P-values
of the interactions are shown.
doi:10.1371/journal.pntd.0004701.g001
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Fig 2. Differential cytokine production betweenMaf- andMtb-infected patients before and after
treatment.Whole blood incubated overnight with medium only (I), revealed differences in the concentrations of
IL12p70 (A), PDGF-ββ (B), MIP-1α (C), IL-15 (D) and IL-8 (E) betweenMtb- andMaf-infected patients at 6
month of treatment. (II) Only ESAT-6/CFP-10 stimulation induced significant differences in cytokine production
betweenMtb- andMaf-infected patients above the background level of IFN-γ (A), IL-2 (B), IL-1ra (C), TNF-α (D),
GM-CSF (E) and Rantes (F). Dot plots show log-2 transformed cytokine concentrations measured with Bio-Plex
assay. Horizontal bars indicate median cytokine concentration by lineage groups,Maf-infected patients (closed
circles, n = 26 and 20) andMtb-infected patients (open circles, n = 49 and 31) respectively at 0 and 6 months of
TB treatment. Log-2 transformed cytokine concentrations were compared between lineage groups using a
random-intercept model adjusted for age, sex and ethnicity, and Sidak multiple comparison correction.
Contrasts analysis was used after estimation to compute the difference in each cytokine concentration between
Maf andMtb-Infected Patients’ Immune Responses after Treatment
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Interactions of cytokines and genes differentially expressed between
Maf- andMtb-infected patients
The direct relationship among the 23 cytokines and genes differentially expressed between the
Maf andMtb-infected patients was analysed using the Ingenuity Pathway Analysis (IPA, QIA-
GEN Redwood City, USA, www.qiagen.com/ingenuity). Ingenuity canonical pathway analysis
identified a high enrichment in the communication between innate and adaptive immune cells.
Analysis of the upstream regulators revealed a very high enrichment (p = 6.6 x 10−21) of the
nuclear factor NF-kappa-B p65 subunit (RELA) that regulates more than half (n = 12) of the
differentially expressed cytokines and genes betweenMaf- andMtb-infected patients post-
treatment. Interestingly, all the cytokines fitted into 2 network functions with the top one con-
taining 13 of the 23 markers and centred on the NFκB complex (Fig 6).
Discussion
We report here a comparison of clinical and immunological responses before and following
standard anti-TB treatment between TB patients infected byMaf andMtb lineages of the
MTBC in The Gambia. We used an unbiased rigorous statistical approach that accounted for
both intra and inter patient’s group variation, experimental condition variability, repeated
measurement over time and corrected for multiple comparison to identify biomarkers that are
associated with MTBC lineage-specific pathogenesis and response to anti-TB treatment. Over-
all, before treatment there were no differences in clinical parameters and differences in very
few cytokine concentrations and gene expression profiles betweenMaf- andMtb-infected
patients. However, after treatment the BMI, CXR, skinfold thickness and immunological
responses were more significantly improved inMtb- than inMaf-infected patients.
The high similarity in the peripheral blood cells populations, clinical presentation, cytokines
production and genes expression profiles before treatment betweenMaf- andMtb-infected
patients further support uniformity in host responses after succumbing to infection, irrespec-
tive of the infecting lineage of MTBC as previously reported [13,15]. This result also suggests
thatMaf andMtb lineages differences may not affect diagnosis of active TB based on the mea-
surement of soluble cytokines.
The pattern of the changes after treatment are indicative of a quicker recovery from disease
inMtb-infected patients, which might be due to their stronger host immunity and/or a better
immediate response to treatment of theMtb-lineage 4 [10]. In contrast, the poorer improve-
ment in the clinical outcome following treatment ofMaf-infected patients could be related to
the immune profile. Higher ratio of monocytes/lymphocytes following treatment has been
attributed to unresolved infection with on-going inflammation [24]. The high IL-12p70 pro-
duction inMaf-patients correlates with the higher expression of IL12A gene, which encodes
IL-12p35, a subunit of IL-12p70 produced by macrophages to induce production of inflamma-
tory cytokines from T helper-1 (Th1) and Th17 cells [25,26]. In addition, the increased TLR9
expression also induces IL-12 production [27] that will further promote prolonged inflamma-
tory processes, which could lead to poor weight gain [28,29] as seen in ourMaf-infected
patients.
IL-15 is a pleiotropic cytokine produced mainly by macrophages, activates a broad range of
cells including T and NK cells [30], and promotes the survival of BALB/c mice infected with
Mtb [31]. Increased MIP-1α levels in unstimulated plasma of HIV-negative TB patients were
lineage groups and usedWald test for assessing the significance at each time point. P-values of the differences
are shown.
doi:10.1371/journal.pntd.0004701.g002
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Fig 3. Kinetics of cytokines production betweenMaf- andMtb-infected groups following treatment. The kinetics of cytokine expression
showing either strong or weak evidence of difference between lineage groups following overnight incubation with Medium alone (I) or ESAT-6/
CFP-10 (II). Line plots show the predicted mean and its 95% confidence interval (95% CI) of log-2 transformed cytokines concentration inMaf-
andMtb-infected groups at 0, 2 and 6 months of treatment. Wald test through contrasts analysis following a random-intercept model adjusted
for age, sex and ethnicity was used to assess interaction between lineage group and time point on cytokine production. The legend showsMaf-
infected group (dashed lines) andMtb-infected group (solid lines) respectively. P-values of the interactions are shown.
doi:10.1371/journal.pntd.0004701.g003
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Fig 4. Gene expression profiles differ betweenMaf- andMtb-infected patients before and after
treatment. dcRT-MLPA was performed on RNA extracted from whole blood incubated overnight with medium
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associated with favourable treatment outcomes [32]. Therefore, the increased IL-15 and MIP-
1α inMtb-infected patient after 2 months of treatment could reflect a better response to treat-
ment in contrast to theMaf-infected patients.
The significantly higher CCL5 (RANTES) level and IL13 and BPI expression inMaf- com-
pared toMtb-infected patients before treatment was not seen post-treatment, implying that
treatment did not amplify the differences in the markers already detected pre-treatment but
rather revealed new markers. Abundance of IL13 has predicted progression to active tuberculo-
sis disease in high-risk groups [33], suggesting higher susceptibility as well as a lower ability to
mount adequate immune response to recover from disease in ourMaf-infected patients. This is
in line with our previous report of immune exhaustion, and higher prevalence among HIV-
positive, severely malnourished and older individuals, ofMaf-infected patients [1,15,16,34,35],
implying thatMafmainly causes diseases in a permissive host environment.
ESAT-6/CFP-10 stimulation induced the greatest differences in cytokines concentration
and genes expressed between the groups post-treatment. These were mainly pro-inflammatory
markers that have previously been associated with protection, such as IFN-γ, and were all sig-
nificantly higher inMtb- thanMaf-infected patients. This suggests that the immune system of
Mtb-infected patients were more capable of mounting a robust response to ESAT-6/CFP-10 on
recovering following anti-TB treatment as previously described [15,36,37]. However, other
studies have reported the opposite [38,39]. Lower cytokine response post-treatment inMaf-
infected patients may reflect a poor immune recovery due to an ineffective response to treat-
ment in this group, or a pre-TB immune suppressed state. This is further supported by a gener-
ally lower cytokine profile in response to all stimulants in this study, as well as corroborates
with the previous finding of increased proportion of HIV-infected amongst patients withMaf-
caused tuberculosis [34].
The enrichment of NF-κB activation-related genes among the differentially expressed bio-
markers between the groups post-treatment is similar to previous reports [40,41]. NF-κB is a
key nuclear transcription factor of pro-inflammatory genes activation [41], which corroborates
our identified cytokines. We have previously reported high enrichment of HNF4-α, which reg-
ulated about 15% of all genes differentially expressed betweenMaf- andMtb-infected patients
post-treatment [13]. Low HNF4-α expression has been associated with worst prognosis of
hepatocellular carcinoma (HCC) through a robust activation of RELA, whereas higher HNF4-
α expression inhibited NF-κB expression and improved HCC outcome [42]. The enrichment
of HNF4-α and NF-κB in our datasets is very interesting. Although we cannot yet establish a
direct connection based on our current data, this might suggests that the dampenedMaf-
infected patient’s pro-inflammatory response to antigen stimulation post-treatment occurs
through the inhibition of NF-κB pathway.
Our study was nested within a platform that has a commendable record of treatment moni-
toring and completion. [43]. Although bothMtb andMaf-infected patients had negative
smears for AFB by the end of the follow up, differences may not have been observed due to
poor sensitivity of the microscopy method used [44]. The more sensitive culture conversion
method is not used to monitor treatment in The Gambia and was therefore not used in our
only (A), ESAT-6/CFP-10 (B) and liveMaf (C). Median gene expression levels (peak areas normalized to
GAPDH and log2 transformed) of the indicated genes are shown in box-and-whisker plots. Equal number of
samples were analysed at 0 and 6 months of treatment in each group ofMaf-infected (n = 20; white boxes) and
Mtb-infected (n = 31; grey boxes) patients, respectively. Log-2 transformed gene expression data were
compared between the groups using contrast analysis following a random-intercept model adjusted for age,
sex and ethnicity, and Sidak multiple comparison correction. Wald test was used to assess the significance at
each time point. P-values of significant differences are shown.
doi:10.1371/journal.pntd.0004701.g004
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Fig 5. Kinetics of gene expression inMaf- andMtb-infected groups following treatment. The expression kinetics of genes
that showed significant differences betweenMaf- andMtb-infected groups following overnight incubation with Medium alone (A),
ESAT-6/CFP-10 (B) and liveMaf (C). Line plots show the predicted mean and its 95% CI of log2 transformed gene expression
levels inMaf- andMtb-infected groups at 0, 2 and 6 months of treatment. Wald test through contrasts analysis following a random-
intercept model adjusted for age, sex and ethnicity was used to assess interaction between lineage group and time point on gene
expression. The legend showsMaf-infected group (dashed lines) andMtb-infected group (solid lines) respectively. P-values of the
interactions are shown.
doi:10.1371/journal.pntd.0004701.g005
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study. In addition, although the drug resistance profile of the infecting organisms was not
tested, The Gambia has a very low prevalence of TB drug resistance determined in the last sur-
vey performed in 2003 [45]. It is therefore unlikely that the different immune profiles observed
post-treatment between the groups was due to drug resistance. Moreover, previous studies
fromWest Africa showed thatMaf is less likely to develop drug resistance compared toMtb
[46–48]. However, future studies should include systematic mycobacterial culture to monitor
anti-TB treatment response and mycobacterial drug susceptibility testing in order to
strengthen this evidence.
There was a striking similarity in the kinetics of cytokines and genes expression between
Mtb- andMaf-infected patients during the first two months, but significant differences at 6
months of treatment. These together with the clinical responses provide a coherent and robust
evidence of differential responses to treatment inMaf- andMtb-infected patients. This pattern
may indicate that the interval for differences to emerge between the groups by 2 months was
Fig 6. Ingenuity network of direct relationship among genes and cytokines differentially expressed betweenMaf-
andMtb-infected patients. Ingenuity network showing 13 of the 23 pro-inflammatory cytokines and genes that were
differentially expressed betweenMaf- andMtb- infected patients, centred on NF-κ complex. Genes or cytokines that were
higher inMtb- compared toMaf- infected patients are depicted in red, those that were lower in green.
doi:10.1371/journal.pntd.0004701.g006
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short and the difference at 6 month of treatment may reflect a slower rate of clinical and immu-
nological disease resolution ofMaf-infected TB patients. The fact that most differences
between the two groups only emerge after 2 months of treatment suggest thatMaf-infected
patient may require longer intensive treatment phase, a longer treatment regimen overall, or
reveals the pre-TB disease immune profile of the individuals. These results suggest thatMaf
leaves a permissive host profiles after treatment with poor lung function and health quality in
general, which might promotes the susceptibility to future disease. It becomes important to
investigateMaf-infected patients long-term recovery post-treatment and their risk of relapse or
re-infection as a permissive host immunity could favour TB disease fromMaf, which remains a
less virulent bacillus [49] but yet has not been outcompeted by otherMtb lineages according to
recent report in West Africa [35,48,50–56]. Moreover,Maf causes up to half of all tuberculosis
cases in West Africa where the same treatment regimen is given irrespective of the infecting
MTBC lineage. New host-directed therapeutic approaches that aim to reduce inflammatory
responses associated with immunopathology might be proven useful for these patients [57,58].
Furthermore, these results demonstrate that the identification and evaluation of immunologi-
cal biomarkers to monitor anti-tuberculosis treatment response in West Africa should consider
the diversity of MTBC lineages.
Studies inMaf non-endemic regions have shown heterogeneous response to TB treatment
depending on the infecting MTBC lineages [6,10,59]. However, other studies in highly hetero-
geneous populations found no effect of MTBC lineages, but rather patient ethnicity was a sig-
nificant determinant for difference in treatment response [9,11]. Clearly, host and bacteria
factors are important determinants for treatment response, therefore stratified approaches to
TB treatment that account for MTBC lineages is required to improve treatment outcome espe-
cially now with clinical trials of shorter drug treatment regimen for TB [14,60].
In conclusion, our data show differences in clinical parameters and immune genes and pro-
teins associated with inflammatory processes recovery betweenMtb- andMaf-infected patients
following anti-tuberculosis treatment. This profile may be an indication of differences in the
resolution of disease or the pre-tuberculosis status of the host immune system. These findings
may have public health relevance for therapeutic and biomarker discovery purposes, and war-
rant further investigation for the use of the identified biomarkers as potential targets for pre-
ventive or therapeutic intervention against tuberculosis.
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